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α-1 Antitrypsin (AAT) deﬁciency is an inher-
ited genetic disorder associated with lung and
liver disease. It is a rare form of panniculitis
and is related to a high risk for development
of jaundice in infants, liver disease in children
and adults, and pulmonary emphysema in
adults (for review, see McBean et al. 2003).
AAT is coded by a single gene on the long
arm of chromosome 14. Codominant allelic
expression results in a hereditary deﬁciency of
AAT, a glycoprotein produced mainly in the
liver. Although there are a number of natu-
rally occurring variants of AAT, the two most
common deﬁciency variants, S and Z, are the
result of point mutations in the AAT gene. In
these variants, the migration of the protein is
retarded. The S variant (Glu264Val) can
result in a 40% deﬁcit in plasma protein lev-
els. However, it has yet to be linked to any
significant clinical disorder. The Z variant
(Glu342Lys) results in severe plasma deﬁciency
and the manifestation of severe progressive
clinical disease. The major function of AAT is
to protect the lung against the enzyme neu-
trophil elastase. In the normal lung, AAT exists
in balance with neutrophil elastase, a prote-
olytic enzyme that digests damaged or aging
cells and microbes. The disruption of this bal-
ance as occurs with AAT deﬁciency reduces or
eliminates the inhibitory antiprotease action of
AAT, and neutrophil elastase activity goes
unchecked. When unregulated, neutrophil
elastase can attack sensitive lung tissue, result-
ing in airway hyperresponsiveness (Malerba et
al. 2003), particularly when the lung is chal-
lenged by stressors that increase levels of neu-
trophil elastase in the respiratory system, such
as tobacco smoke (Hutchison et al. 2002),
environmental irritants, and infection. Over
time, the resulting tissue damage can result in
deterioration of lung function, leading to
emphysema, chronic bronchitis, chronic
obstructive pulmonary disease (COPD),
bronchiectasis, and asthma (Eden et al. 1997,
2003; Lee et al. 2002; Parfrey et al. 2003;
Piitulainen and Sveger 2002).
Current treatment for AAT deficiency
often involves augmentation of the AAT
protein itself via intravenous infusion of
Prolastin, which is puriﬁed AAT derived from
pooled human plasma (Sandhaus 1993, 2001;
Stoller et al. 2003). Typically indicated in
patients with AAT deﬁciency–related emphy-
sema, this correction of the biochemical imbal-
ance in the respiratory system can help slow or
halt the progression of deterioration in lung
function. Currently, few data exist suggesting
further development of gene therapy as a
mechanism to combat this disease (Brigham
et al. 2000; Dasi et al. 2001; Flotte 2002; Metz
et al. 2002; Song et al. 2001; Stecenko and
Brigham 2003; Stoll et al. 2001). However, at
this time, treatment modalities for AAT deﬁ-
ciency–related respiratory disorders, beyond
AAT augmentation therapy, often include
behavior and lifestyle changes (e.g., smoking
cessation, avoidance of environmental irritants
and infections, exercise) and other therapies
associated with the treatment of obstructive
lung disease, including bronchodilators, corti-
costeroids, and supplemental oxygen. In severe
cases, lung volume reduction surgery and lung
transplantation have also been successfully
employed.
Although the mechanism at work is not
yet fully understood, AAT deﬁciency also leads
to liver disease in many patients, including
hepatitis, cirrhosis, and liver failure, particu-
larly in individuals with the homozygous ZZ
(PiZ) AAT allele. In PiZ individuals, the low
circulating levels of AAT appear to be due to
the accumulation of abnormally folded AAT
protein within the hepatocytes. Approximately
12–15% of Alphas (persons suffering from
AAT deficiency) experience liver disease.
Approximately 10% of newborns with the PiZ
allele have liver disease that leads to fatal child-
hood cirrhosis (Alpha-1 Association 2002).
Persons with the null-null allele, who produce
no AAT at all, do not appear to experience
liver disease, which would support the hypoth-
esis that the accumulation of abnormal AAT in
the endoplasmic reticulum of hepatocytes may
be the driving pathologic factor in AAT deﬁ-
ciency–related liver disease. Prolastin is not
used to treat AAT deﬁciency–related liver dis-
ease. The only available treatment for individ-
uals with end-stage liver disease resulting from
AAT deﬁciency is liver transplantation, which
has been successful in some patients with
severe AAT deﬁciency–related liver disease. In
addition to clinical pathologies associated with
lung and liver disease, AAT deﬁciency has also
been associated with necrotizing panniculitis
and vasculitis, particularly Wegener’s granulo-
matosis (Lonardo et al. 2002).
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α-1 Antitrypsin (AAT) deﬁciency is an inherited genetic disorder currently diagnosed in approxi-
mately 5,000 people in the United States. Although some individuals with AAT deficiency are
asymptomatic, the condition often leads to deterioration of lung function in adults and is associated
with emphysema, asthma, chronic obstructive pulmonary disease, and other respiratory diseases. In
children, AAT deficiency can result in severe liver disease, including fatal cirrhosis in newborn
infants. Although much is known about the clinical pathology of AAT deﬁciency, researchers are
just beginning to characterize environmental, occupational, and genetic modifiers affecting the
onset and progression of diseases related to AAT deﬁciency. On 19 August 2002, a group of basic
scientists, clinicians, environmental health researchers, and public interest groups gathered at the
National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina, to
discuss ongoing research on these topics. The goals of this workshop were to a) assess the present
state of knowledge regarding environmental and occupational risk factors contributing to AAT deﬁ-
ciency morbidity and mortality, b) deﬁne future research needs in this area, and c) explore collabo-
rative opportunities to advance understanding of risk factors affecting the progression of AAT
deﬁciency–related disease. Participants agreed that new research initiatives in these areas represent
an opportunity to beneﬁt both basic science, through enhanced understanding of gene–environ-
ment interaction, and the AAT deﬁciency patient community, through innovative new approaches
to disease management and treatment. Key words: alpha-1 antitrypsin deﬁciency, chronic obstructive
pulmonary disease, emphysema, environmental risk factors, gene–environment interactions, genetic
testing, liver disease, neutrophil elastase, occupational health. Environ Health Perspect
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Research | Meeting ReportMany believe that this disease often goes
undetected or misdiagnosed, especially in the
early stages. To address many of the concerns
of AAT deficiency patients and to raise the
awareness of the disease with the public,
researchers, and funding agencies, the Alpha-1
Foundation was founded as a patient and
research advocacy group, based in Miami,
Florida. The foundation estimates that
roughly 5,000 cases of AAT deficiency have
been diagnosed in the United States (Alpha-1
Foundation 2002) and is actively pursuing
improvements in this area, including a tar-
geted detection program in Florida with the
goal of testing every patient in the state with
COPD or unexplained liver disease, and every
adult and adolescent with chronic asthma.
This foundation, in collaboration with acade-
mic researchers and clinicians and with the
National Institute of Environmental Health
Sciences (NIEHS), organized a workshop that
would bring together these various interested
parties to discuss the current knowledge base
and to raise questions speciﬁcally with regard to
the contribution of environmental factors in the
manifestation and progression of the disease.
Workshop Summary
On 19 August 2002, a multidisciplinary group
of interested parties gathered at the NIEHS in
Research Triangle Park, North Carolina, to
exchange information and ideas pertaining to
the investigation of environmental, occupa-
tional, and genetic risk factors that may con-
tribute to the onset and progression of AAT
deficiency–related disease. The workshop,
titled “Environmental, Occupational, and
Genetic Risk Factors for Alpha-1 Antitrypsin
Deﬁciency,” was sponsored by the NIEHS, the
Ofﬁce of Rare Disease Research of the National
Institutes of Health (Bethesda, MD), the
Alpha-1 Foundation, and AlphaNet, a not-for-
proﬁt health management company serving the
AAT community. The overarching goals of the
workshop were to a) assess the present state of
knowledge regarding environmental and occu-
pational risk factors contributing to AAT deﬁ-
ciency morbidity and mortality, b) define
future research needs in this area, and c) explore
collaborative opportunities to advance under-
standing of risk factors affecting the progression
of AAT deﬁciency–related disease.
John Walsh, current president of the
Alpha-1 Foundation and one of several par-
ticipants who were Alphas themselves, set the
tone for the day’s deliberations in his opening
remarks. He stressed the importance of
expanding research efforts on AAT deﬁciency
and developing new therapies or preventive
interventions. His hope was that new thera-
peutic options would emerge from research
initiatives on AAT deﬁciency designed to clarify
the role of environmental risk factors in modu-
lating the onset and progression of the disease:
The importance of this workshop to our commu-
nity is signiﬁcant. Right now in our community, we
have one therapy, and it’s in critical short supply.
We think if we can focus on. . . environmental risk
factors, we’re going to be able to positively impact
the course of this devastating chronic illness. We
look at this as a preventative form of medicine, and
maybe we can stop the progression of the disease
completely, which would be great. . . . At least
maybe we can slow down the progression.
The ﬁrst session of the conference, moderated
by Richard R. Sharp of the NIEHS, provided
an overview of the natural history of AAT
deﬁciency, diagnosis, and treatment options.
Robert Sandhaus, Clinical Director and
Executive Vice President of the Alpha-1
Foundation, summarized signiﬁcant develop-
ments in the history of AAT lung and liver
disease (Table 1). After this history, Sandhaus
discussed diagnostic criteria and common ther-
apeutic strategies (Sandhaus 2002). James
Donohue, a pulmonologist at the University of
North Carolina at Chapel Hill and the second
speaker in the session (Donohue 2002), pre-
sented a clinician’s point of view about diag-
nostic challenges (Table 2), the management of
persons with AAT deﬁciency, and the use of
augmentation therapy (Schluchter et al. 2000).
James Stocks of the University of Texas Health
Center at Tyler concluded the session by
describing ongoing efforts to improve AAT
augmentation therapy and expand the scope of
therapeutic options available to persons with
AAT deﬁciency (Stocks 2002).
With the workshop’s attention focused on
new research initiatives, the second session,
moderated by G. Jean Harry of the NIEHS,
centered on the current state of research regard-
ing the treatment of AAT deficiency. Bruce
Trapnell of the University of Cincinnati and
the Alpha-1 Foundation presented an overview
of the foundation’s research program (Trapnell
2002). After this presentation, Charlie Strange
of the Medical University of South Carolina
provided more details (Strange 2002b) about
the Alpha-1 Foundation’s Research Registry
(http://www.alpha1registry.org), which has
served as an important resource for the devel-
opment of AAT deficiency–related research.
The registry was initiated in 1996 and within
the ﬁrst year had only 100 patients participat-
ing. This increased to approximately 500
patients by 1998, and by 2000 the registry
contained 900 patients. During the years
2001–2002, an additional 1,000 or so patients
were registered, bringing the total to 2,062
participants. Also during this session, Frederick
de Serres, a former NIEHS scientist who has
AAT deﬁciency, outlined his ongoing research
on the worldwide distribution of alleles associ-
ated with AAT deﬁciency (de Serres 2002a).
By analyzing data from more than 400 control
cohorts in peer-reviewed studies in 60 coun-
tries covering 11 major geographic regions, de
Serres has uncovered evidence suggesting a
much more widespread distribution of the two
most common deﬁciency alleles, PiS and PiZ
(de Serres 2002b; de Serres et al. 2003)
The third session of the conference reviewed
research on environmental, occupational, and
genetic risk factors associated with AAT deﬁ-
ciency, particularly factors affecting the develop-
ment of COPD and other lung diseases. Edwin
Silverman of Harvard University described his
and other investigators’ work on the genetics
of COPD in AAT-deﬁcient and nondeﬁcient
subjects (Silverman 2002). In addition to his
ongoing research into the genetics of early-onset
COPD, which may shed light on some aspects
of AAT deﬁciency, he and collaborators at eight
clinical centers are presently in the early stages
of a study seeking to identify genetic modiﬁers
of AAT deﬁciency. The second speaker in the
session, Sverre Vedal of the National Jewish
Medical and Research Center, explored various
methodologies used in studies conducted on
ambient air pollution and occupational expo-
sures believed to be related to COPD, with an
emphasis on how various study designs could
be used in similar investigations of environ-
mental risk factors for AAT deﬁciency (Vedal
2002). Building upon that foundation, Annyce
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Table 1. Signiﬁcant events in the history of AAT deﬁciency.
< 1963 Familial emphysema initially described in Sweden
1963 Laurell and Eriksson describe association between familial emphysema and deﬁciency of α1
1964 Gross describes animal model of emphysema caused by intratracheally instilled papain
1965–1967 Appreciation of role of elastase
1965–1967 Fagerhol describes allelic variation of AAT
1967 Janoff describes neutrophil elastase
1969 Sharp describes association with neonatal cirrhosis
1971–1975 Inhibition of neutrophil elastase by AAT; role of oxidants
1980s α1 Augmentation therapy; epidemiology of α1 explored
Speciﬁc references in the history of AAT deﬁciency are cited by Sandhaus (1993, 2001, 2002).
Table 2. Clinical symptoms suggesting AAT deﬁciency.
COPD
Asthma
Family history of AAT deﬁciency
Unexplained chronic liver disease
Bronchiectasis
Panniculitis
Unexplained vasculitis, particularly of Wegener’s 
granulomatosis type
If these conditions are seen in nonsmokers of any age, or if
COPD occurs at age 30–55 in smokers, the likelihood of AAT
deﬁciency is considerable. Adapted from Donohue (2002).Mayer of National Jewish Medical and Research
Center presented an overview of existing
research into environmental and occupational
exposures and AAT deﬁciency (Mayer 2002),
arguing that although the literature contains sev-
eral important studies to date, more research is
needed (Mayer and Newman 2001; Mayer et al.
2000). The session concluded with University
of Florida bioethicist Ray Moseley’s exploration
of the complex ethical and legal issues involved
in identifying genetically susceptible popula-
tions, particularly with respect to informed con-
sent and the testing of children and young
adults for genetic conditions (Moseley 2002).
The workshop culminated with a panel
discussion about future research on environ-
mental and occupational risk factors associated
with AAT deficiency. The goals of this con-
cluding session, moderated by Lee Newman of
National Jewish Medical and Research Center,
were to identify critical unanswered research
questions and to explore strategies for bringing
environmental health researchers, the patient
community, and funding agencies together in
efforts to answer some of those questions.
Recommendations
Participants agreed that the natural history of
AAT deﬁciency is still not well understood. As
Sandhaus expressed it, “Clearly, … the epi-
demiology of Alpha-1 and [its] natural history
is one of the areas of great deﬁcit that’s been
identiﬁed all along, and it still is in need of a
great deal of further research.” For example,
there is a need to identify early biomarkers of
AAT deﬁciency, including markers that might
help to explain why some Alphas remain
asymptomatic whereas others develop emphy-
sema and/or liver disease. Similarly, although
the Z allele appears necessary for the develop-
ment of AAT deﬁciency–related emphysema,
it is not sufﬁcient in and of itself to account
for the onset of disease. Trapnell and others
suggested that it is important to look for other
genetic and/or environmental factors at work
that may contribute to the differential mani-
festation of various adverse effects within the
AAT patient population.
Several participants stressed the idea that
identiﬁcation of early biomarkers, additional
genetic factors, and environmental contribu-
tions would directly serve the AAT commu-
nity. Such information would allow for earlier
preventive interventions, such as lifestyle
adjustments, career planning, and avoidance
of harmful environmental exposures. A more
precise definition of risk factors might also
allow for targeted screening and detection of
persons at risk.
In addition, there was consensus that
research exploring the role of environmental
factors in the initiation, manifestation, and pro-
gression of clinical symptoms in people with
AAT deﬁciency represents a clear opportunity
to advance basic research and simultaneously
provide benefit to patients. The AAT defi-
ciency patient population clearly represents a
subpopulation susceptible to numerous airway
stimulants as well as other inﬂammatory agents
or processes. The detailed examination of this
population will contribute to the clinical popu-
lation with regard to diagnosis, prevention, and
maintenance of the disease as well as providing
information regarding factors and agents that
may produce adverse effects in various suscep-
tible subpopulations. Just as the identiﬁcation
of an association between plasma deﬁciency of
AAT and emphysema led to the proteinase–
antiproteinase hypothesis of lung disease, any
additional understanding of the role of aber-
rant protein polymerization in AAT defi-
ciency could contribute to the development
of novel therapeutic strategies (Carrell and
Lomas 2002; Devlin et al. 2001; Lomas and
Mahadeva 2002; Perlmutter 2002). de Serres,
speaking from the dual perspectives of an
Alpha and a scientist, expressed this conver-
gence of interests:
All people are not created equal, and some of us are
uniquely susceptible.… I think it’s a matter of
developing the right approaches in the laboratory to
see if there are ways of evaluating quickly the effect
of either environmental exposure to chemicals or to
particulates, rather than waiting long-term for us to
develop asthma, bronchiectasis, and the variety of
other problems that plague most of us.
Participants also agreed that the Alpha-1
Foundation’s Research Registry (http://www.
alpha1registry.org; Stoller et al. 2000; Strange
2002a) is a major asset for researchers inter-
ested in examining gene–environment interac-
tions. Many individuals in the registry are
highly sensitive to environmental exposures,
and their AAT deﬁciency status is well char-
acterized, making this a unique research
resource. Several speakers did express concerns
about inherent biases in the registry, however,
that could limit its utility as a research tool.
For example, the registry may be biased
toward individuals of higher socioeconomic
status, who are likely to live and work in less
harmful environments, potentially biasing
data in the direction of the null hypothesis
when examining the effects of environmental
exposures. Additionally, because persons in
the registry have been identified largely as
a result of health problems indicative of
advanced disease, participants in the registry
are likely to be less healthy than the larger
population of Alphas, which could be prob-
lematic in assessing the natural history of AAT
deficiency. Although participants acknowl-
edged these limitations, many felt the registry
could continue to play an important role in
future research and that innovative study
designs might be developed for examining
environmental and occupational risk factors in
the context of the registry.
In addition to these efforts, a number of
participants supported the development of
large cohort studies designed to overcome the
ascertainment biases of collections such as the
Alpha-1 Registry (Stoller et al. 2000; Strange
2002a). Such cohort studies could shed light
on the natural history of AAT deﬁciency and
suggest key environmental and genetic factors
involved in the progression of AAT defi-
ciency–related disease. Silverman drew atten-
tion to a study of Swedish newborns with
AAT deficiency (Sveger 1978; Sveger and
Eriksson 1995; Sveger and Thelin 2000;
Sveger et al. 1999). In that study, 200,000
Swedish infants were screened for AAT deﬁ-
ciency in the early 1970s, with nearly 200
Alphas identified (Laurell and Sveger 1975;
Sveger 1978). These persons are periodically
reexamined to track the impact of AAT deﬁ-
ciency on their health. Because the Swedish
cohort is still years away from yielding deﬁni-
tive answers to many questions about the nat-
ural history of AAT deficiency, however,
Silverman and others suggested that it may be
appropriate to undertake large population
screening programs to acquire a non-ascer-
tainment-biased set of AAT-deﬁcient subjects.
This suggestion was embraced by John Walsh
of the Alpha-1 Foundation, who asked:
Do we wait thirty years for the Swedish newborns
study to be done, or do we take that bold step and
spend whatever amount of money it’s going to take
to do an appropriate population study to ascertain
what the real prevalence or incidence is? … If the
answer is, “We’d better do that,” then let’s do it
and let’s not wait. Thirty years is not acceptable to
anybody that I know that has Alpha-1.
AAT deﬁciency is clearly more prevalent than
previously thought, and the information
exchanged among the participants at this
workshop showed that investigation of the
inﬂuence of environmental and occupational
risk factors on the onset and exacerbation of
AAT deficiency–related disease will be an
important new direction in research associated
with this often fatal condition. New informa-
tion in that arena will complement simultane-
ous progress made in the understanding of
genetic susceptibility to AAT deﬁciency, and of
the disease process itself, both of which are in
critical need of additional research. At the same
time, research attention must be paid to the
often complex ethical, legal, and social issues
raised by genetic testing, gene–environment
interactions, and the identiﬁcation of environ-
mental and occupational risk factors, as they
affect this uniquely susceptible population.
Innovative and imaginative research initiatives
resulting from collaborations among the vari-
ous interested groups hold the promise of one
day providing new answers to the many open
questions remaining about AAT deficiency,
and contributing to new management strate-
gies, improved therapies, and an eventual cure.
Meeting Report | AAT deficiency workshop
Environmental Health Perspectives  •  VOLUME  111 |  NUMBER  14 |  November 2003                                                                                                                            1751REFERENCES
Alpha-1 Association. 2002. Frequently Asked Questions.
Available: http://www.alpha1.org/what/geninfo_faq.htm
[accessed 2 August 2002].
Brigham KL, Lane KB, Meyrick B, Stecenko AA, Strack S, Cannon
DR, et al. 2000. Transfection of nasal mucosa with a normal
alpha-1 antitrypsin (AAT) gene in AAT deﬁcient subjects: com-
parison with protein therapy. Hum Gene Ther 11:1023–1032.
Carrell RW, Lomas DA. 2002. Alpha-1-antitrypsin deficiency—a
model for conformational diseases. N Engl J Med 346:45–53.
Dasi F, Benet M, Crespo A, Alino SF. 2001. Asialofetuin liposome-
mediated human 1- antitrypsin gene transfer in vivo results in
stationary long-term gene expression. J Mol Med 79:205–212.
Devlin GL, Parfrey H, Tew DJ, Lomas DA, Bottomley SP. 2001.
Prevention of polymerization of M and Z 1-antitrypsin (1-AT)
with trimethylamine N-oxide. Implications for the treatment of
alpha1-AT deﬁciency. Am J Respir Cell Mol Biol 24:727–732.
de Serres FJ. 2002a. Worldwide racial and ethnic distribution: an
overview of published genetic empidemiological surveys.
Presented at Environmental, Occupational, and Genetic Risk
Factors for Alpha-1 Antitrypsin Deficiency, 19 August 2002,
Research Triangle Park, NC.
———. 2002b. Worldwide racial and ethnic distribution of alpha-
1-antitrypsin deficiency: summary of an analysis of pub-
lished genetic epidemiologic surveys. Chest 122:1818–1829.
de Serres FJ, Blanco I, Fernandez-Bustillo E. 2003. Genetic
epidemiology of alpha-1 antitrypsin deficiency in southern
Europe: France, Italy, Portugal and Spain. Clin Genet
63:490–509.
Donohue JF. 2002. Diagnosis, care, and treatment of patients with
alpha-1 antitrypsin deficiency. Presented at Environmental,
Occupational, and Genetic Risk Factors for Alpha-1 Antitrypsin
Deﬁciency, 19 August 2002, Research Triangle Park, NC.
Eden E, Hammel J, Rouhani RN, Brantly ML, Barker AF, Buist AS,
et al. 2003. Asthma features in severe alpha-1-antitrypsin deﬁ-
ciency: experience of the National Heart, Lung, and Blood
Institute registry. Chest 123:765–771.
Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH,
et al. 1997. Atopy, asthma, and emphysema in patients with
severe α-1-antitrypsin deficiency. Am J Respir Crit Care
Med 156:68–74.
Flotte TR. 2002. Recombinant adeno-associated virus gene ther-
apy for cystic fibrosis and [alpha]1-antitrypsin deficiency.
Chest 121:98S–102S.
Hutchison DC, Cooper D. 2002. Alpha-1-antitrypsin deficiency:
smoking, decline in lung function and implications for thera-
peutic trials. Respir Med 96:872–880.
Laurell CB, Sveger T. 1975. Mass screening of newborn Swedish
infants for alpha antitrypsin deficiency. Am J Hum Genet
27:213–217.
Lee P, Gildea TR, Stoller JK. 2002. Emphysema in nonsmokers:
alpha 1-antitrypsin deﬁciency and other causes. Cleve Clin J
Med 69:928–929.
Lomas DA, Mahadeva R. 2002. α1-Antitrypsin polymerization and
the serpinopathies: pathobiology and prospects for therapy.
J Clin Invest 110:1585–1590.
Lonardo A, Medicina D, Leonelli M, Bagni A, Callea F. 2002.
Intestinal Wegener’s granulomatosis in a patient with severe
alpha-1-antitrypsin deﬁciency resulting from a unique combi-
nation of two deﬁciency alleles (PiZ and PiMProcida). Eur J
Gastroenterol Hepatol 14:1389–1392.
Malerba M, Randaeli A, Cerini L, Tantucci C, Grassi V. 2003.
Airway hyperresponsiveness in a large group of subjects
with alpha1-antitrypsin deficiency: a cross-sectional con-
trolled study. J Intern Med 253:351–358.
Mayer AS. 2002. Genetic and environmental modulation of COPD
in alpha-1 antitrypsin deﬁciency. Presented at Environmental,
Occupational, and Genetic Risk Factors for Alpha-1
Antitrypsin Deficiency, 19 August 2002, Research Triangle
Park, NC.
Mayer AS, Newman LS. 2001. Genetic and environmental modu-
lation of chronic obstructive pulmonary disease. Respir
Physiol 128:3–11.
Mayer AS, Stoller JK, Bucher Bartelson B, James Ruttenber A,
Sandhaus RA, Newman LS. 2000. Occupational exposure
risks in individuals with PI*Z alpha(1)-antitrypsin deﬁciency.
Am J Respir Crit Care Med 162:553–558.
McBean J, Sable A, Maude J, Robinson-Boston L. 2003. Alpha1-
antitrypsin deﬁciency panniculitis. Cutis 71:205–209.
Metz R, DiCola M, Kurihara T, Bailey A, Frank B, Roecklein B, et al.
2002. Mode of action of RNA/DNA oligonucleotides: progress
in the development of gene repair as a therapy for alpha(1)-
antitrypsin deﬁciency. Chest 121:91S-97S.
Moseley R. 2002. Identifying genetically susceptible populations:
ethical and policy issues. Presented at Environmental,
Occupational, and Genetic Risk Factors for Alpha-1 Antitrypsin
Deﬁciency, 19 August 2002, Research Triangle Park, NC.
Parfrey H, Mahadeva R, Lomas DA. 2003. Alpha(1)-antitrypsin
deficiency, liver disease and emphysema. Int J Biochem
Cell Biol 35:1009–1014.
Perlmutter DH. 2002. Liver injury in alpha-1-antitrypsin deﬁciency:
an aggregated protein induced mitochondrial injury. J Clin
Invest 110:1579–1583.
Piitulainen E, Sveger T. 2002. Respiratory symptoms and lung
function in young adults with severe alpha(1)-antitrypsin
deﬁciency (PiZZ). Thorax 57:705–708.
Sandhaus RA. 1993. Alpha 1-antitrypsin augmentation therapy.
Agents Actions 42(suppl):97–102.
———. 2001. Alpha(1)-antitrypsin deficiency therapy: pieces of
the puzzle. Chest 119:676–678.
———. 2002. History of alpha-1 lung and liver disease. Presented
at Environmental, Occupational, and Genetic Risk Factors for
Alpha-1 Antitrypsin Deficiency, 19 August 2002, Research
Triangle Park, NC.
Schluchter MD, Stoller JK, Barker AF, Buist AS, Crystal RG,
Donohue JF, et al. 2000. Feasibility of a clinical trial of aug-
mentation therapy for alpha(1)-antitrypsin deficiency. The
Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J
Respir Crit Care Med 161:796–801.
Silverman EK. 2002. Genetics of COPD in alpha-1 deﬁcient and non-
deﬁcient subjects. Presented at Environmental, Occupational,
and Genetic Risk Factors for Alpha-1 Antitrypsin Deﬁciency, 19
August 2002, Research Triangle Park, NC.
Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte TR. 2001.
Stable therapeutic serum levels of human alpha-1 antitrypsin
(AAT) after portal vein injection of recombinant adeno-associ-
ated virus (rAAV) vectors. Gene Ther 8:1299–1306.
Stecenko AA, Brigham KL. 2003. Gene therapy progress and
prospects: alpha-1 antitrypsin. Gene Ther 10:95–99.
Stocks JM. 2002. New approaches to the management of alpha-1
antitrypsin deficiency. Presented at Environmental,
Occupational, and Genetic Risk Factors for Alpha-1 Antitrypsin
Deﬁciency, 19 August 2002, Research Triangle Park, NC.
Stoll SM, Sclimenti CR, Baba EJ, Meuse L, Kay MA, Calos MP.
2001. Epstein-Barr virus/human vector provides high-level,
long-term expression of α1-antitrypsin in mice. Mol Ther
4:122–129.
Stoller JK, Brantly M, Fleming LE, Bean JA, Walsh J. 2000.
Formation and current results of a patient-organized registry
for alpha(1)-antitrypsin deﬁciency. Chest 118:843–848.
Stoller JK, Fallat R, Schluchter MD, O’Brien RG, Connor JT, Gross
N, et al. 2003. Augmentation therapy with alpha1-antitrypsin:
patterns of use and adverse events. Chest 123:1425–1434.
Strange C. 2002a. Alpha-1 Foundation research registry: from the
past to the future. J Pediatr Gastroenterol Nutr 34:1.
———. 2002b. Alpha-1 research registry—data and patient cohort
for research studies. Presented at Environmental, Occupational,
and Genetic Risk Factors for Alpha-1 Antitrypsin Deﬁciency, 19
August 2002, Research Triangle Park, NC.
Sveger T. 1978. Alpha 1-antitrypsin deﬁciency in early childhood.
Pediatrics 62:22–25.
Sveger T, Eriksson S. 1995. The liver in adolescents with alpha-1
antitrypsin deﬁciency. Hepatology 22:514–517.
Sveger T, Thelin T. 2000. A future for neonatal alpha1-antitrypsin
screening. Acta Paediatr 89:628–631.
Sveger T, Thelin T, McNeil TF. 1999. Neonatal alpha1-antitrypsin
screening: parents’ views and reactions 20 years after
the identification of the deficiency state. Acta Paediatr
88:315–318.
Trapnell BC. 2002. Overview of the Alpha-1 Foundation research
program. Presented at Environmental, Occupational, and
Genetic Risk Factors for Alpha-1 Antitrypsin Deficiency, 19
August 2002, Research Triangle Park, NC.
Vedal S. 2002. Environment and airway disease risk. Presented at
Environmental, Occupational, and Genetic Risk Factors for
Alpha-1 Antitrypsin Deficiency, 19 August 2002, Research
Triangle Park, NC.
Meeting Report | Sharp et al.
1752  VOLUME  111 |  NUMBER  14 |  November 2003  •  Environmental Health Perspectives
Workshop Participants
Richard R. Sharp, Co-Chair
Baylor College of Medicine
Houston, TX
Lee Newman, Co-Chair
National Jewish Medical and Research Center
Denver, CO
Gayle Allison
AlphaNet Coordinator
Hurricane, WV
Bob Chufo
Pittsburgh, PA
Frederick de Serres
NIEHS
Research Triangle Park, NC
Ryan Dickson
Medical University of South Carolina
Charleston, SC
James Donohue
University of North Carolina at Chapel Hill
Chapel Hill, NC
Symma Finn
Alpha-1 Foundation
Miami, FL
G. Jean Harry
NIEHS
Research Triangle Park, NC
Annyce Mayer
National Jewish Medical and Research Center
Denver, CO
Amy McGrath
Bayer Corporation
Research Triangle Park, NC
Ray Moseley
University of Florida College of Medicine
Gainesville, FL
Miriam O’Day
Alpha-1 Foundation
Miami, FL
Adrian Reuben
MUSC Medical Center
Charleston, SC
Ken Samonds
University of Massachusetts
Amherst, MA
Robert A. Sandhaus
Alpha-1 Foundation
Miami, FL
Edwin Silverman
Harvard University
Boston, MA
James M. Stocks
University of Texas Health Center
Tyler, TX
Charlie Strange
Medical University of South Carolina
Charleston, SC
Bruce C. Trapnell
Children’s Hospital and Medical Center
Cincinnati, OH
Gerard M. Turino
Columbia University
New York, NY
Sverre Vedal
National Jewish Medical and Research Center
Denver, CO
John W. Walsh
Alpha-1 Foundation
Miami, FL